he Noida-based Institute of Cellular Therapies (ICT) has accepted an offer from Malaysia to offer targeted "dendritic cell" therapy to sufferers after effectively treating lots of cancer patients in India.

ICT has invented a novel treatment, which makes use of cell-based cancer immuno-therapy - treatment utilizing the patient's own mononuclear cells transmuted into cancer-specific dendritic cells.

With the help of this therapy, medical specialists take out the mononuclear (CD14+) cells from the patient's blood, change these cells into cancer-fighting cells and insert them back in the patients body.

Senior doctor and ICT director Jamal A. Khan said, "Dendritic cell therapy is a targeted add-on treatment for cancer patients. It helps the recovery process and reduces the chance of relapse of the disease among patients. We are happy that the Malaysian government authorities now want this treatment to be made available there.”

Mr. Khan stated that his institute will frame-up a cell culture research laboratory for clinical experiments in Malaysia shortly.

He added that ICT will work in partnership with Malaysia's health ministry to establish the lab and making this cure popular. Malaysia is presently importing the medication from ICT and after the laboratory comes up in the country, ICT will produce the medicine - Denvax - in Malaysia.

"This treatment is not available in Malaysia and it will work as an additional facility for the people of that country. Our therapy targets the cancer cells without affecting other cells around the cancerous part of the body," he added.

Khan said Denvax targets only the cancer cells without damaging the healthy ones.

Denvax helps in rectifying the failed immune surveillance and instructs the immune system to distinguish and destroy cancer cells. (With Input from Agencies)